Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.06 |
-1.02 |
-0.96 |
-1539.29% |
2024-02-06 |
2023-12 |
-0.78 |
-1.24 |
-0.46 |
-58.97% |
2023-11-29 |
2023-09 |
-0.7 |
-1.03 |
-0.33 |
-47.14% |
2023-08-07 |
2023-06 |
-0.58 |
-0.96 |
-0.38 |
-65.52% |
2023-05-02 |
2023-03 |
-0.65 |
0.45 |
1.1 |
169.23% |
2023-02-06 |
2022-12 |
1.14 |
-0.39 |
-1.53 |
-134.21% |
Date |
Firm |
Action |
From |
To |
2023-09-18 |
Citigroup |
Upgrade |
|
Neutral |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-07 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-07 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-07 |
Chardan Capital |
Upgrade |
Buy |
Buy |
2023-07-20 |
TD Cowen |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-30 |
ANZALONE CHRISTOPHER RICHARD |
Chief Executive Officer |
3.72M |
Sale |
2024-01-10 |
FERRARI MAURO |
Director |
60.78K |
Sale |
2024-01-10 |
GIVEN DOUGLAS BRUCE |
Director |
129.71K |
Sale |
2024-03-31 |
HAMILTON JAMES C |
Officer |
204.85K |
Sale |
2024-03-19 |
LU HONGBO B |
Director |
33.68K |
Purchase |
2024-03-05 |
MYSZKOWSKI KENNETH ALLEN |
Chief Financial Officer |
400.60K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
12.81M |
456.85M |
11.95% |
2023-06-29 |
Vanguard Group Inc |
10.97M |
391.25M |
10.24% |
2023-06-29 |
State Street Corporation |
5.51M |
196.40M |
5.14% |
2023-06-29 |
JP Morgan Chase & Company |
2.88M |
102.73M |
2.69% |
2023-06-29 |
FMR, LLC |
2.72M |
97.15M |
2.54% |
2023-06-29 |
Invesco Ltd. |
2.23M |
79.47M |
2.08% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
iShares Core S&P Midcap ETF |
3.35M |
90.08M |
3.13% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.23M |
115.06M |
3.01% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.62M |
93.50M |
2.45% |
2023-08-30 |
iShares Russell 2000 ETF |
2.34M |
64.63M |
2.18% |
2023-07-30 |
Invesco Global Opportunities Fund |
2.00M |
69.04M |
1.87% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
1.98M |
54.77M |
1.85% |
Split |
Date |
0.1 : 1 |
2011-11-17 |
0.01538 : 1 |
2004-01-15 |